Navigation Links
Pfenex Reports Second Quarter 2014 Results and Provides Business Update
Date:8/29/2014

t June 30, 2014 and December 31, 2013, respectively; 3,556,186 shares issued andoutstanding; $13,815,111 liquidation preference49,40049,200Redeemable convertible Series A-1 preferred stock, par value $0.001,5,000,000 and 4,978,662 shares authorized at June 30, 2014 and December 31, 2013, respectively;, 4,978,661 shares issued andoutstanding; $16,470,071 liquidation preference64,54063,980Stockholders' equity (deficit):Common stock, $.001 par value, 30,000,000 and 12,514,224 shares authorized at June 30, 2014 and December 31, 2013, respectively; 1,571,473 and 1,541,781 shares issued and outstanding at June 30, 2014 and December 31, 2013, respectively42Additional paid-in capital--Accumulated deficit(98,847)(94,453)Total stockholders' equity (deficit)(98,843)(94,451)Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)$
29,088
$
31,813
Note: The Pfenex Condensed Statement of Operations and Balance Sheet for the period ended June 30, 2014 does not reflect the Pfenex initial public offering that closed on July 29, 2014. 

Logo - http://photos.prnewswire.com/prnh/20140715/127348


'/>"/>
SOURCE Pfenex Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Pfenex Inc. Awards Glide Pharma Development Contract for a Solid Formulation of Recombinant Anthrax Vaccine
2. Pfenex Inc. Awards Paragon Bioservices a Contract for cGMP Manufacturing of its Recombinant Protective Antigen (rPA), for Phase 1 Clinical Trial of its Anthrax Vaccine
3. Pfenex Awarded Contract For Development Of Next Generation rPA-Based Anthrax Vaccine
4. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
5. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
6. Interleukin Genetics Reports Third Quarter 2011 Financial Results
7. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
8. Nile Therapeutics Reports 2011 Third Quarter Financial Results
9. Pharmasset Reports Fiscal Year End 2011 Financial Results
10. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
11. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... August 28, 2015 , ... Proove Biosciences ... the International Spine Intervention Society’ s 23rd Annual Scientific Meeting (ASM). ... 2015. With a focus on evidence-based research and clinical application, the event gathered ...
(Date:8/28/2015)... 28, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. ... company focused on the development of autologous cell ... ended June 30, 2015, corporate highlights, and near-term ... are available at www.sedar.com ,  www.edgar.com ... "RepliCel expects to launch its RCS-01 treatment ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... Since the initial launch of FireflySci Inc. ... quirky humor and excellent customer service. Images such as the Fonz in a lab ... add some flavor to the humdrum spectroscopy field. , FireflySci is proud to ...
(Date:8/27/2015)... ... August 27, 2015 , ... Capital Edge Consulting , a ... is pleased to announce their ranking as one of the top 5000 companies listed ... private companies across the nation. , “It is truly an honor to be recognized ...
Breaking Biology Technology:Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 2Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 3Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 4RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3
... in three years, the Best of State Program,s, ... company in the Medical Innovation category, , , ... LLC (ABL), developer of a new class of products based on ... has won the 2009 Utah Best of State award in the ...
... SAN DIEGO, June 5, 2009 Arena Pharmaceuticals, Inc. (Nasdaq: ... scheduled to present at the 8th Annual Needham Life Sciences Conference ... Pacific Time) at the New York Palace Hotel in ... Chief Financial Officer, is scheduled to provide an overview of the ...
... Expansion in Medical Imaging Management , For Hospitals, ... June 4 Optimal Reading Services Group, Inc., a ... hospitals, imaging centers and radiology groups, announced today that ... substantial investment in Optimal. The investment provides Optimal with ...
Cached Biology Technology:American Biotech Labs(R) Garners 2009 Utah Best of State Award 2American Biotech Labs(R) Garners 2009 Utah Best of State Award 3Arena Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference 2Arena Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference 3Optimal Reading Services Group, Inc. Receives Investment from Health Evolution Partners 2Optimal Reading Services Group, Inc. Receives Investment from Health Evolution Partners 3
(Date:8/3/2015)... SAN JOSE, Calif. , Aug. 3, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that members ... investment community at the Pacific Crest Global Technology Leadership ... Mountain Time. The conference will be held at the ... The presentation may include forward-looking information. ...
(Date:7/31/2015)... , Chine, 31 juillet 2015 La ... www.icg-10.org ) sera organisée par le BGI du ... Shenzhen en Chine. La ... son inauguration en 2006, l,ICG est devenue l,une ... le domaine des « omiques » et c,est aussi la ...
(Date:7/31/2015)... The 10 th International Conference on Genomics ... 22-25, 2015, in Shenzhen , ... 10 th anniversary this year. Since its inauguration in ... annual meetings in the ,omics, fields, and is one of ... ICG-10 focuses on recent breakthroughs and advances in ,omics, ...
Breaking Biology News(10 mins):La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3The 10th International Conference on Genomics (ICG-10) to Open in October 2
... form of nanoparticles has been designed by Northwestern Medicine scientists to ... on cancer. This is the first cancer drug tested while in ... test. The scientists designed ... a chemotherapy drug to fertility and can be easily used to ...
... Scientists at the University of Liverpool are embarking on a ... warming on the ecosystems of the seas surrounding North West ... that shelf-seas the seas surrounding continental land masses - ... warming of the seas might affect it. The study ...
... University of Florida study of nearly 5,000 Haiti bird ... arrival 6,000 years ago didn,t cause the island,s birds ... became displaced during a mass extinction event following the ... evidence shows some species were more resilient than others. ...
Cached Biology News:New chemo drug gentler on fertility, tougher on cancer 2New chemo drug gentler on fertility, tougher on cancer 3Scientists awarded £3M to study the way Northwest European seas absorb carbon 2UF fossil bird study on extinction patterns could help today's conservation efforts 2UF fossil bird study on extinction patterns could help today's conservation efforts 3
... Transformation Buffer Set are convenient methods for ... for simple and highly efficient DNA transformation. ... for heat shocking and related procedures. Instead, ... adding DNA to Z-Competent cells and incubating ...
... Diagnostics Universal Amplicon Detection Assay ... in the qualitative detection and ... in vitro nucleic acid ... not to be used in ...
Propidium Iodide: {3,8-diamino-5-[3-(diethylmethylammonio)propyl]-6-phenylphenanthridinium diodide}. Antifade Solution: p-Phenylenediamine and glycerol in PBS solution. 2.5ug/mL Propidium Iodide (PI)...
Apoptosis Detection Systems and Reagents...
Biology Products: